SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

Summary

The investigators propose a phase II single-arm study on using stereotactic body radiation therapy in combination with durvalumab for inoperable/unresectable hepatocellular carcinoma. In addition, the investigators will also measure the change in number and intensity of PD-L1-positive circulating tumor cells before and after stereotactic body radiation therapy and durvalumab and evaluate their correlation with treatment response.

Timeline

Start

2020-10-15

Primary completion

2023-12-31

Completion

2024-12-31

Drugs

Indications